Cargando…

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)

Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katsiki, Niki, Vrablik, Michal, Banach, Maciej, Gouni-Berthold, Ioanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143414/ https://www.ncbi.nlm.nih.gov/pubmed/37111334 http://dx.doi.org/10.3390/ph16040577

Ejemplares similares

Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Accuracy of low-density lipoprotein cholesterol estimation at very low levels
por: Quispe, Renato, et al.
Publicado: (2017)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
por: Lehoux, Dario, et al.
Publicado: (2023)

Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?
por: Sabouret, Pierre, et al.
Publicado: (2022)

Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial
por: Berthold, Heiner K., et al.
Publicado: (2014)

Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients
por: Penumarthy, Swati, et al.
Publicado: (2013)

Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography
por: WANG, Yao, et al.
Publicado: (2020)

Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
por: Elsadek Seaoud, Elshaimaa Aly M., et al.
Publicado: (2022)

Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population
por: Tian, Li, et al.
Publicado: (2010)

Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction
por: Sigdel, Manoj, et al.
Publicado: (2012)

Low-density lipoprotein cholesterol lowering treatment: the current approach
por: Crismaru, Irina, et al.
Publicado: (2020)

Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis
por: Chu, Chih-Sheng, et al.
Publicado: (2020)

The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses
por: Moriyama, Kengo
Publicado: (2020)

Low Density Lipoprotein-Cholesterol/High Density Lipoprotein-Cholesterol Ratio Predicts Plaque Vulnerability in Patients With Stable Angina
por: Kim, Jeong Hun, et al.
Publicado: (2012)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

Triglycerides, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol in rats exposed to premium motor spirit fumes
por: Aberare, Ogbevire L., et al.
Publicado: (2011)

Low density Lipoprotein cholesterol target: Changing goal posts
por: Bantwal, Ganapathi, et al.
Publicado: (2012)

Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital
por: Nanda, Sunil Kumar, et al.
Publicado: (2017)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Of statins and low-density lipoprotein cholesterol, “fats” and fiction
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2016)

Visit-to-visit variability in low-density lipoprotein cholesterol
por: Sookaromdee, Pathum, et al.
Publicado: (2019)

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
por: Massy, Ziad A., et al.
Publicado: (2019)

Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion
por: Dannecker, Corinna, et al.
Publicado: (2021)

Low-Density Lipoprotein Cholesterol and Mortality in Peritoneal Dialysis
por: Wu, Xianfeng, et al.
Publicado: (2022)

New insights into the mechanism of low high-density lipoprotein cholesterol in obesity
por: Wang, Hao, et al.
Publicado: (2011)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

High-density lipoprotein cholesterol: How High
por: Rajagopal, G., et al.
Publicado: (2012)

Methods of Low-Density Lipoprotein-Cholesterol Measurement: Analytical and Clinical Applications
por: Islam, S.M. Touhidul, et al.
Publicado: (2022)

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes
por: Hayashi, Toshiyuki, et al.
Publicado: (2023)

Comparison of soymilk and probiotic soymilk effects on serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in diabetic Wistar rats
por: Babashahi, Mina, et al.
Publicado: (2015)

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy
por: Oka, Ryo, et al.
Publicado: (2018)

The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis
por: Lin, Tong, et al.
Publicado: (2020)

Why Should We Measure Low-Density Lipoprotein Cholesterol Directly? Comparison of Low-Density Lipoprotein Cholesterol Assessment by Friedewald Estimation, and Direct Measurement
por: Cohen, Hofit
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qqs7jha133l56h1vpippbml8h2